Beta-thalassemia by Galanello, Renzo & Origa, Raffaella
Galanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
http://www.ojrd.com/content/5/1/11
Open Access REVIEW
BioMed  Central
© 2010 Galanelloa and Origaa; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Review Beta-thalassemia
Renzo Galanello* and Raffaella Origa
Abstract
Beta-thalassemias are a group of hereditary blood disorders characterized by anomalies in the synthesis of the beta 
chains of hemoglobin resulting in variable phenotypes ranging from severe anemia to clinically asymptomatic 
individuals. The total annual incidence of symptomatic individuals is estimated at 1 in 100,000 throughout the world 
and 1 in 10,000 people in the European Union. Three main forms have been described: thalassemia major, thalassemia 
intermedia and thalassemia minor. Individuals with thalassemia major usually present within the first two years of life 
with severe anemia, requiring regular red blood cell (RBC) transfusions. Findings in untreated or poorly transfused 
individuals with thalassemia major, as seen in some developing countries, are growth retardation, pallor, jaundice, poor 
musculature, hepatosplenomegaly, leg ulcers, development of masses from extramedullary hematopoiesis, and 
skeletal changes that result from expansion of the bone marrow. Regular transfusion therapy leads to iron overload-
related complications including endocrine complication (growth retardation, failure of sexual maturation, diabetes 
mellitus, and insufficiency of the parathyroid, thyroid, pituitary, and less commonly, adrenal glands), dilated 
myocardiopathy, liver fibrosis and cirrhosis). Patients with thalassemia intermedia present later in life with moderate 
anemia and do not require regular transfusions. Main clinical features in these patients are hypertrophy of erythroid 
marrow with medullary and extramedullary hematopoiesis and its complications (osteoporosis, masses of 
erythropoietic tissue that primarily affect the spleen, liver, lymph nodes, chest and spine, and bone deformities and 
typical facial changes), gallstones, painful leg ulcers and increased predisposition to thrombosis. Thalassemia minor is 
clinically asymptomatic but some subjects may have moderate anemia. Beta-thalassemias are caused by point 
mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent 
(beta0) synthesis of the beta chains of hemoglobin (Hb). Transmission is autosomal recessive; however, dominant 
mutations have also been reported. Diagnosis of thalassemia is based on hematologic and molecular genetic testing. 
Differential diagnosis is usually straightforward but may include genetic sideroblastic anemias, congenital 
dyserythropoietic anemias, and other conditions with high levels of HbF (such as juvenile myelomonocytic leukemia 
and aplastic anemia). Genetic counseling is recommended and prenatal diagnosis may be offered. Treatment of 
thalassemia major includes regular RBC transfusions, iron chelation and management of secondary complications of 
iron overload. In some circumstances, spleen removal may be required. Bone marrow transplantation remains the only 
definitive cure currently available. Individuals with thalassemia intermedia may require splenectomy, folic acid 
supplementation, treatment of extramedullary erythropoietic masses and leg ulcers, prevention and therapy of 
thromboembolic events. Prognosis for individuals with beta-thalassemia has improved substantially in the last 20 years 
following recent medical advances in transfusion, iron chelation and bone marrow transplantation therapy. However, 
cardiac disease remains the main cause of death in patients with iron overload.
Disease name and synonyms
The term thalassemia is derived from the Greek, thalassa
(sea) and haima (blood). Beta-thalassemia includes three
main forms: Thalassemia Major, variably referred to as
"Cooley's Anemia" and "Mediterranean Anemia", Thalas-
semia Intermedia and Thalassemia Minor also called
"beta-thalassemia carrier", "beta-thalassemia trait" or
"heterozygous beta-thalassemia". Apart from the rare
dominant forms, subjects with thalassemia major are
homozygotes or compound heterozygotes for beta0 or
beta+  genes, subjects with thalassemia intermedia are
mostly homozygotes or compound heterozygotes and
subjects with thalassemia minor are mostly heterozy-
gotes.
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Definition
Beta-thalassemia syndromes are a group of hereditary
blood disorders characterized by reduced or absent beta
globin chain synthesis, resulting in reduced Hb in red
blood cells (RBC), decreased RBC production and ane-
mia. Most thalassemias are inherited as recessive traits.
Beta-thalassemias can be classified into:
- Beta-thalassemia
• Thalassemia major
•Thalassemia intermedia
•Thalassemia minor
- Beta-thalassemia with associated Hb anomalies
• HbC/Beta-thalassemia
• HbE/Beta-thalassemia
• HbS/Beta-thalassemia (clinical condition more sim-
ilar to sickle cell disease than to thalassemia major or
intermedia)
- Hereditary persistence of fetal Hb and beta-thalas-
semia
- Autosomal dominant forms
- Beta-thalassemia associated with other manifesta-
tions
• Beta-thalassemia-tricothiodystrophy
• X-linked thrombocytopenia with thalassemia
Epidemiology
Beta-thalassemia is prevalent in Mediterranean coun-
tries, the Middle East, Central Asia, India, Southern
China, and the Far East as well as countries along the
north coast of Africa and in South America. The highest
carrier frequency is reported in Cyprus (14%), Sardinia
(10.3%), and Southeast Asia [1]. The high gene frequency
of beta-thalassemia in these regions is most likely related
to the selective pressure from Plasmodium falciparum
malaria [1]. Population migration and intermarriage
between different ethnic groups has introduced thalas-
semia in almost every country of the world, including
Northern Europe where thalassemia was previously
absent. It has been estimated that about 1.5% of the global
population (80 to 90 million people) are carriers of beta-
thalassemia, with about 60,000 symptomatic individuals
born annually, the great majority in the developing world.
The total annual incidence of symptomatic individuals is
estimated at 1 in 100,000 throughout the world and 1 in
10,000 people in the European Union. However, accurate
data on carrier rates in many populations are lacking,
particularly in areas of the world known or expected to be
heavily affected [2]. According to Thalassemia Interna-
tional Federation, only about 200,000 patients with thala-
ssemia major are alive and registered as receiving regular
treatment around the world [3]. The most common com-
bination of beta-thalassemia with abnormal Hb or struc-
tural Hb variant with thalassemic properties is HbE/beta-
thalassemia which is most prevalent in Southeast Asia
where the carrier frequency is around 50%.
Clinical description
The phenotypes of homozygous or genetic heterozygous
compound beta-thalassemias include thalassemia major
and thalassemia intermedia. Individuals with thalassemia
major usually come to medical attention within the first
two years of life and require regular RBC transfusions to
survive. Thalassemia intermedia includes patients who
present later and do not require regular transfusion.
Except in the rare dominant forms, heterozygous beta-
thalassemia results in the clinically silent carrier state.
HbE/beta-thalassemia and HbC/beta-thalassemia exhibit
a great range in terms of diversity of phenotypes and
spectrum of severity.
Beta-thalassemia major
Clinical presentation of thalassemia major occurs
between 6 and 24 months. Affected infants fail to thrive
and become progressively pale. Feeding problems, diar-
rhea, irritability, recurrent bouts of fever, and progressive
enlargement of the abdomen caused by spleen and liver
enlargement may occur. In some developing countries,
where due to the lack of resources patients are untreated
or poorly transfused, the clinical picture of thalassemia
major is characterized by growth retardation, pallor,
jaundice, poor musculature, genu valgum, hepatospleno-
megaly, leg ulcers, development of masses from
extramedullary hematopoiesis, and skeletal changes
resulting from expansion of the bone marrow. Skeletal
changes include deformities in the long bones of the legs
and typical craniofacial changes (bossing of the skull,
prominent malar eminence, depression of the bridge of
the nose, tendency to a mongoloid slant of the eye, and
hypertrophy of the maxillae, which tends to expose the
upper teeth).
If a regular transfusion program that maintains a mini-
mum Hb concentration of 9.5 to 10.5 g/dL is initiated,
growth and development tends to be normal up to 10 to
12 years [3]. Transfused patients may develop complica-
tions related to iron overload. Complications of iron
overload in children include growth retardation and fail-
ure or delay of sexual maturation. Later iron overload-
related complications include involvement of the heart
(dilated myocardiopathy or rarely arrythmias), liver
(fibrosis and cirrhosis), and endocrine glands (diabetes
mellitus, hypogonadism and insufficiency of the parathy-
roid, thyroid, pituitary, and, less commonly, adrenal
glands) [4]. Other complications are hypersplenism,
chronic hepatitis (resulting from infection with viruses
that cause hepatitis B and/or C), HIV infection, venous
thrombosis, and osteoporosis. The risk for hepatocellular
carcinoma is increased in patients with liver viral infec-Galanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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tion and iron overload [5]. Compliance with iron chela-
tion therapy (see later) mainly influences frequency and
severity of the iron overload-related complications. Indi-
viduals who have not been regularly transfused usually
die before the second-third decade. Survival of individu-
als who have been regularly transfused and treated with
appropriate chelation extends beyond age of 40 years.
Cardiac disease caused by myocardial siderosis is the
most important life-limiting complication of iron over-
load in beta-thalassemia. In fact, cardiac complications
are the cause of the deaths in 71% of the patients with
beta-thalassemia major [6].
Beta-thalassemia intermedia
Individuals with thalassemia intermedia present later
than thalassemia major, have milder anemia and by defi-
nition do not require or only occasionally require transfu-
sion. At the severe end of the clinical spectrum, patients
present between the ages of 2 and 6 years and although
they are capable of surviving without regular blood trans-
fusion, growth and development are retarded. At the
other end of the spectrum are patients who are com-
pletely asymptomatic until adult life with only mild ane-
mia. Hypertrophy of erythroid marrow with the
possibility of extramedullary erythropoiesis, a compensa-
tory mechanism of bone marrow to overcome chronic
anemia, is common. Its consequences are characteristic
deformities of the bone and face, osteoporosis with
pathologic fractures of long bones and formation of
erythropoietic masses that primarily affect the spleen,
liver, lymph nodes, chest and spine. Enlargement of the
spleen is also a consequence of its major role in clearing
damaged red cells from the bloodstream. Extramedullary
erythropoiesis may cause neurological problems such as
spinal cord compression with paraplegia and intratho-
racic masses. As a result of ineffective erythropoiesis and
peripheral hemolysis, thalassemia intermedia patients
may develop gallstones, which occur more commonly
than in thalassemia major [7]. Patients with thalassemia
intermedia frequently develop leg ulcers and have an
increased predisposition to thrombosis as compared to
thalassemia major, especially if splenectomised. Such
events include deep vein thrombosis, portal vein throm-
bosis, stroke and pulmonary embolism [8].
Although individuals with thalassemia intermedia are
at risk of iron overload secondary to increased intestinal
iron absorption, hypogonadism, hypothyroidism and dia-
betes are not common [9]. Women may have successful
spontaneous pregnancies. However, if blood transfusions
are necessary during pregnancy, those never or minimally
transfused are at risk of developing hemolytic alloanti-
bodies and erythrocyte autoantibodies. Intrauterine
growth retardation, despite a regular transfusion regi-
men, has been reported [10]. Cardiac involvement in
thalassemia intermedia results mainly from a high-output
state and pulmonary hypertension, while systolic left ven-
tricle function is usually preserved [11]. Pseudoxantoma
elasticum, a diffuse connective tissue disorder with vas-
cular manifestation caused by degeration of the elastic
lamina of the arterial wall and calcium deposition, has
been described in such patients [12].
Beta-thalassemia minor
Carriers of thalassemia minor are usually clinically
asymptomatic but sometimes have a mild anemia. When
both parents are carriers there is a 25% risk at each preg-
nancy of having children with homozygous thalassemia.
Dominant beta-thalassemia
In contrast with the classical recessive forms of beta-thal-
assemia, which lead to a reduced production of normal
beta globin chains, some rare mutations result in the syn-
thesis of extremely unstable beta globin variants which
precipitate in erythroid precursors causing ineffective
erythropoiesis. These mutations are associated with a
clinically detectable thalassemia phenotype in the
heterozygote and are therefore referred to as dominant
beta-thalassemias [13]. The presence of hyper-unstable
Hb should be suspected in any individual with thalas-
semia intermedia when both parents are hematologically
normal, or in families with a pattern of autosomal domi-
nant transmission of the thalassemia intermedia pheno-
type. Beta globin gene sequencing establishes the
diagnosis.
Beta-thalassemia associated with other Hb anomalies
The interaction of HbE and beta-thalassemia results in
thalassemia phenotypes ranging from a condition indis-
tinguishable from thalassemia major to a mild form of
thalassemia intermedia. Depending on the severity of
symptoms three categories may be identified:
- Mild HbE/beta-thalassemia: It is observed in about
15% of all cases in Southeast Asia. This group of patients
maintains Hb levels between 9 and 12 g/dl and usually
does not develop clinically significant problems. No
treatment is required.
- Moderately severe HbE/beta-thalassemia: The major-
ity of HbE/beta-thalassemia cases fall into this category.
The Hb levels remain at 6-7 g/dl and the clinical symp-
toms are similar to thalassemia intermedia. Transfusions
are not required unless infections precipitate further ane-
mia. Iron overload may occur.
- Severe HbE/beta-thalassemia: The Hb level can be as
low as 4-5 g/dl. Patients in this group manifest symptoms
similar to thalassemia major and are treated as thalas-
semia major patients.
Patients with HbC/beta-thalassemia may live free of
symptoms and be diagnosed during routine tests. When
present, clinical manifestations are anemia and enlarge-Galanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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ment of the spleen. Blood transfusions are seldom
required. Microcytosis and hypochromia are found in
every case. The blood film shows distinctive Hb C crys-
tals with straight parallel edges, target cells, and irregu-
larly contracted cells with features of thalassemia such as
microcytosis.
The association of hereditary persistence of fetal Hb
(HPFH) with beta-thalassemia mitigates the clinical man-
ifestations which vary from normal to thalassemia inter-
media.
Individuals with HbS/beta-thalassemia have a clinical
course similar to that of Hb SS.
Beta-thalassemia associated with other features
In rare instances the beta-thalassemia defect does not lie
in the beta globin gene cluster. In cases in which the beta-
thalassemia trait is associated with other features, the
molecular lesion has been found either in the gene
encoding the transcription factor TFIIH (beta-thalas-
semia trait associated with tricothiodystrophy) or in the
X-linked transcription factor GATA-1 (X-linked throm-
bocytopenia with thalassemia) [14,15].
Etiology
More than 200 mutations have been so far reported; the
large majority are point mutations in functionally impor-
tant regions of the beta globin gene [16,17]. Deletions of
the beta globin gene are uncommon. The beta globin
gene mutations cause a reduced or absent production of
beta globin chains. A list of common mutations according
to the severity and ethnic distribution is reported in Table
1.
Genetic modifiers
Modifier genes are defined as genetic variants that lead to
differences in disease phenotype. In homozygous beta-
thalassemia, primary genetic modifiers, affecting the clin-
ical severity of the disease, include genetic variants able
to reduce the globin chain imbalance, therefore resulting
in a milder form of thalassemia. These factors are the
presence of silent or mild beta-thalassemia alleles associ-
ated with a high residual output of beta globin, the co-
inheritance of alpha thalassemia and/or of genetic deter-
minants able to sustain a continuous production of
gamma globin chains (HbF) in adult life [18]. Some beta-
thalassemia mutations (i.e. deletion and non deletion
delta beta-thalassemia, deletions of the 5' region of the
beta globin gene) increase "per se" the gamma globin gene
output. Other mutations increasing HbF production are
those associated with deletional and non-deletional
HPFH linked to the beta globin gene cluster. Recently, the
genome-wide association approach, particularly studying
quantitative trait loci (QTL) which cause elevated HbF,
have revealed genetic elements (i.e. polymorphism in
BCL11A gene and in the HBS1LCMYB intergenic region)
unlinked to beta globin gene cluster, able to modify the
severity of the homozygous beta zero thalassemia [19].
The clinical phenotype of homozygous beta-thalas-
semia may also be modified by the co-inheritance of
other genetic variants mapping outside the globin clus-
ters. These secondary genetic modifiers influence mainly
the complications of the thalassemia phenotype. Several
secondary genetic modifiers have been identified in the
recent years. The presence of (TA)7 polymorphism in the
promoter region of the uridine diphosphate-glucurono-
syltransferase gene, which in the homozygous state is
associated with the Gilbert syndrome, is a risk factor for
the development of cholelitiasis in thalassemia major and
intermedia patients [20,21]. Other candidate genes for
modification of the thalassemia phenotype are the apoli-
poprotein E ε4 allele and some HLA haplotypes, which
seem to be genetic risk factors for left ventricular failure
in homozygous beta-thalassemia [22,23]. Less consistent
data have been reported for genes involved in iron metab-
olism (i.e. C282Y and H63D HFE gene mutations), proba-
bly because their effect on iron overload is hidden as a
result of treatment (i.e. secondary iron overload from red
cell transfusion and iron chelation), and for genes associ-
ated with bone metabolism [24-26]. Recently, a polymor-
phism in glutathione-Stransferase M1 gene has been
associated with an increased risk of heart iron overload in
thalassemia major [27].
In some instances, heterozygous beta-thalassemia may
lead to the thalassemia intermedia phenotype instead of
the asymptomatic carrier state. Most of these patients
have excess functional alpha globin genes (alpha gene
triplication or quadruplication) which increases the
imbalance in the ratio of alpha/non-alpha globin chain
synthesis [18,28].
Pathophysiology
The reduced amount (beta+) or absence (beta0) of beta
globin chains result in a relative excess of unbound alpha
globin chains that precipitate in erythroid precursors in
the bone marrow, leading to their premature death and
hence to ineffective erythropoiesis. The degree of globin
chain reduction is determined by the nature of the muta-
tion at the beta globin gene located on chromosome 11.
Peripheral hemolysis contributing to anemia is less
prominent in thalassemia major than in thalassemia
intermedia, and occurs when insoluble alpha globin
chains induce membrane damage to the peripheral eryth-
rocytes. Anemia stimulates the production of erythropoi-
etin with consequent intensive but ineffective expansion
of the bone marrow (up 25 to 30 times normal), which in
turn causes the typical previously described bone defor-
mities. Prolonged and severe anemia and increasedGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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Table 1: Common types of beta-thalassemia: severity and ethnic distribution.
Population β-gene mutation Severity
Indian -619 del β0
Mediterranean -101 CTTβ ++
Black -88 CTTβ ++
Mediterranean; African -87 CTGβ ++
Japanese -31 ATGβ ++
African -29 ATGβ ++
Southeast Asian -28 ATCβ ++
Mediterranean; Asian Indian IVS1-nt1 GTAβ 0
East Asian; Asian Indian IVS1-nt5 GTCβ 0
Mediterranean IVS1-nt6 TTCβ +/++
Mediterranean IVS1-nt110 GTAβ +
Chinese IVS2-nt654 CTTβ +
Mediterranean IVS2-nt745 CTGβ +
Mediterranean codon 39 CTTβ 0
Mediterranean codon 5 -CT β0
Mediterranean; African-American codon 6 -A β0
Southeast Asian codon 41/42 -TTCT β0
African-American AATAAA to AACAAA β++
Mediterranean AATAAA to AATGAA β++
Mediterranean codon 27 GTT Hb (Hb Knossos) β++
Southeast Asian codon 79 G>A (Hb E) β++
Malaysia Codon 19 G>A (Hb Malay) 
β0:complete absence of beta globin on the affected allele
β+:residual production of beta globin (around 10%)
β++:very mild reduction in beta globin productionGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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erythropoietic drive also result in hepatosplenomegaly
and extramedullary erythropoiesis.
Hereditary transmission
The beta-thalassemias are inherited in an autosomal
recessive manner. The parents of an affected child are
obligate heterozygotes and carry a single copy of a dis-
ease-causing beta globin gene mutation. At conception,
each child of heterozygotes parents has 25% chance of
being affected, 50% chance of being an asymptomatic car-
rier, and 25% chance of being unaffected and not carrier.
The parents of the proband have a 1 in 4 (25%) risk of
having further affected children in each pregnancy.
Dominant forms of beta-thalassemia, associated with
mutations that result in the production of highly unstable
beta globulin variants and leading to a clinically manifest-
ing phenotype of beta-thalassemia in heterozygotes, have
been discussed above in the clinical description section
[13].
Diagnosis
Clinical Diagnosis
Thalassemia major is usually suspected in an infant
younger than two years of age with severe microcytic
anemia, mild jaundice and hepatosplenomegaly. Thalas-
semia intermedia presents at a later age with similar but
milder clinical findings. Carriers are usually asymptom-
atic, but sometimes may have mild anemia.
Hematologic Diagnosis
RBC indices show microcytic anemia. Thalassemia
major is characterized by reduced Hb level (<7 g/dl),
mean corpuscolar volume (MCV) > 50 < 70 fl and mean
corpuscolar Hb (MCH) > 12< 20 pg. Thalassemia inter-
media is characterized by Hb level between 7 and 10 g/dl,
MCV between 50 and 80 fl and MCH between 16 and 24
pg. Thalassemia minor is characterized by reduced MCV
and MCH, with increased Hb A2 level [29].
Peripheral blood smear
• Affected individuals show RBC morphologic
changes [microcytosis, hypochromia, anisocytosis,
poikilocytosis (spiculated tear-drop and elongated
cells)], and nucleated RBC (i.e., erythroblasts). The
number of erythroblasts is rela ted to the degree of
anemia and is markedly increased after splenectomy.
• Carriers have less severe RBC morphologic changes
than affected individuals. Erythroblasts are normally
not seen.
Qualitative and quantitative Hb analysis (by cellulose
acetate electrophoresis and DE-52 microchromatography
or HPLC) identifies the amount and type of Hb present.
The Hb pattern in beta-thalassemia varies according to
beta-thalassemia type. In beta0 thalassemia, homozygotes
HbA is absent and HbF constitutes the 92-95% of the
total Hb. In beta+ thalassemia homozygotes and beta+/
beta0 genetic compounds HbA levels are between 10 and
30% and HbF between 70-90%. HbA2 is variable in beta
thalassemia homozygotes and it is enhanced in beta thal-
assemia minor.
Hb electrophoresis and HPLC also detect other hemo-
globinopathies (S, C, E, OArab, Lepore) that may interact
with beta-thalassemia.
Molecular Genetic Analysis
• The prevalence of a limited number of mutations in
each population has greatly facilitated molecular
genetic testing.
Commonly occurring mutations of the beta globin
gene are detected by PCR-based procedures [30]. The
most commonly used methods are reverse dot blot
analysis or primer-specific amplification, with a set of
probes or primers complementary to the most com-
mon mutations in the population from which the
affected individual originated.
• If targeted mutation analysis fails to detect the
mutation, beta globin gene sequence analysis can be
used to detect mutations in the beta globin gene.
Differential diagnosis
Few conditions share similarities with homozygous beta-
thalassemia:
• The genetically-determined sideroblastic anemias
are easily differentiated because of ring sideroblasts in
the bone marrow and variably elevated serum con-
centration of erythrocyte protoporphyrin. Most
sideroblastic anemias are associated with defects in
the heme biosynthetic pathway, especially delta-ami-
nolevulinic acid synthase.
• Congenital dyserythropoietic anemias do not have
high HbF and do have other distinctive features, such
as multinuclearity of the red blood cell precursors.
• A few acquired conditions associated with high HbF
(juvenile chronic myelomonocytic leukemia with nor-
mal kariotype, aplastic anemia both congenital and
acquired during the recovery phase) may be mistaken
for beta-thalassemia, even though they have very
characteristic clinical and hematological features.
Typical beta-thalassemia carriers are identified by anal-
ysis of RBC indices, which shows microcytosis (low
MCV) and reduced content of Hb per red cell (low
MCH), and by qualitative and quantitative Hb analysis,
which displays the increase of HbA2.
Pitfalls in carrier identification by hematologic testing
are:
•  Coinheritance of alpha-thalassemia, which may
normalize the RBC indices. However, in alpha/beta
double heterozygotes, the HbA2 concentrationGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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remains in the beta-thalassemia carrier range and
thus is diagnostic. Therefore, HbA2  determination
should always be performed for betathalassemia car-
rier identification.
•  Coinheritance of delta-thalassemia, which may
reduce to normal the increased Hb A2 levels typical
of the beta-thalassemia carrier state. Double
heterozygosity for delta- and betathalassemia can be
distinguished from the most common alpha-thalas-
semia carrier state by globin chain synthesis or globin
gene analysis.
• Silent mutations, i.e., very mild mutations associated
with consistent residual output of Hb beta chains and
with normal RBC indices and normal or borderline
HbA2. The above reported groups of carriers are
referred to as atypical carriers (see Table 1 β++ muta-
tions).
When the hematologic analysis is abnormal, molecular
genetic testing of beta globin gene is performed to iden-
tify the disease-causing mutation [30].
Genetic counseling and prenatal diagnosis Preven-
tion of beta-thalassemia is based on carrier identification,
genetic counseling and prenatal diagnosis [31]. Carrier
detection has been previously described. Genetic coun-
seling provides information for individuals and at risk
couples (i.e. both carriers) regarding the mode of inheri-
tance, the genetic risk of having affected children and the
natural history of the disease including the available
treatment and therapies under investigation. Prenatal
diagnosis for pregnancies at increased risk is possible by
analysis of DNA extracted from fetal cells obtained by
amniocentesis, usually performed at approximately 15-18
weeks' gestation or chorionic villi sampling at 11 weeks'
gestation. Both disease-causing alleles must be identified
before prenatal testing can be performed. Analysis of fetal
cells in maternal blood and analysis of fetal DNA in
maternal plasma for the presence of the father's mutation
are currently under investigation [32,33]. Preimplantation
genetic diagnosis may be available for families in which
the disease-causing mutations have been identified.
Management of thalassemia major
Transfusions
The goals of transfusion therapy are correction of ane-
mia, suppression of erythropoiesis and inhibition of gas-
trointestinal iron absorption, which occurs in non
transfused patients as a consequence of increased,
although ineffective, erythropoiesis. The decision to start
transfusion in patients with confirmed diagnosis of thala-
ssemia should be based on the presence of severe anemia
(Hb < 7 g/dl for more than two weeks, excluding other
contributory causes such as infections). However, also in
patients with Hb > 7 g/dl, other factors should be consid-
ered, including facial changes, poor growth, evidence of
bony expansion and increasing splenomegaly. When pos-
sible, the decision to start regular transfusions should not
be delayed until after the second- third year, due to the
risk of developing multiple red cell antibodies and subse-
quent difficulty in finding suitable blood donors. Several
different transfusional regimens have been proposed over
the years, but the most widely accepted aims at a pre-
transfusional Hb level of 9 to 10 g/dl and a post-transfu-
sion level of 13 to 14 g/dl. This prevents growth impair-
ment, organ damage and bone deformities, allowing
normal activity and quality of life [3,4]. The frequency of
transfusion is usually every two to four weeks. Shorter
intervals might further reduce the overall blood require-
ment, but are incompatible with an acceptable quality of
life. The amount of blood to be transfused depends on
several factors including weight of the patient, target
increase in Hb level and hematocrit of blood unit. Appro-
priate graphs and formulae to calculate the amount of
blood to be transfused are available [3]. In general, the
amount of transfused RBC should not exceed 15 to 20
ml/kg/day, infused at a maximum rate of 5 ml/kg/hour, to
avoid a fast increase in blood volume. To monitor the
effectiveness of transfusion therapy, some indices should
be recorded at each transfusion, such as pre- and post-
transfusion Hb, amount and hematocrit of the blood unit,
daily Hb fall and transfusional interval. These measure-
ments enable two important parameters to be calculated:
red cell requirement and iron intake. Dedicated comput-
erized programs (Webthal) are available to monitor
transfused thalassemia patients accurately [34]. Although
red cell transfusions are lifesavers for patients with thala-
ssemia, they are responsible for a series of complications
and expose the patients to a variety of risks. Iron overload
is the most relevant complication associated with trans-
fusion therapy. Other adverse events associated with red
cell transfusions are summarized in Table 2.
Assessment and treatment of Iron overload
Patients maintained on a regular transfusion regimen
progressively develop clinical manifestations of iron over-
load: hypogonadism (35-55% of the patients), hypothy-
roidism (9-11%), hypoparathyroidism (4%), diabetes (6-
10%), liver fibrosis, and heart dysfunction (33%) [35,36].
Iron status should be accurately assessed in order to eval-
uate its clinical relevance, the need for treatment, and the
timing and monitoring of chelation therapy. The iron sta-
tus of multitransfused patients can be assessed by several
methods. Serum ferritin has in general been found to cor-
r e la t e  wit h body ir on st or es  [ 37] .  H o weve r ,  as  a  s ingle
value it is not always reliable because, being an acute-
phase reactant, it is influenced by other factors such as
inflammatory disorders, liver disease, malignancy.
Despite this, serial measurements of serum ferritin
remain a reliable and the easiest method to evaluate ironGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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overload and efficacy of chelation therapy. Determination
of liver iron concentration in a liver biopsy specimen
shows a high correlation with total body iron accumula-
tion and is considered the gold standard for the evalua-
tion of iron overload [38]. However, liver biopsy is an
invasive technique with the possibility (though low) of
complications. Moreover, we should consider that the
presence of hepatic fibrosis, which commonly occurs in
individuals with iron overload and HCV infection, and
heterogeneous liver iron distribution can lead to possible
false negative results [39]. In recent years, nuclear mag-
netic resonance imaging (MRI) techniques for assessing
iron loading in the liver and heart have been introduced
[40-43]. R2 and T2* parameters have been validated for
liver iron concentration. Cardiac T2* is reproducible,
transferable between different scanners, correlates with
cardiac function, and relates to tissue iron concentration.
Clinical utility of T2* in monitoring patients with siderotic
cardiomyopathy has been demonstrated [44,45]. Calibra-
tion of T2* in the heart will be available in the near future.
Magnetic biosusceptometry (SQUID), is another option
for a reliable measurement of hepatic iron concentration
[46]; however, magnetic susceptometry is presently avail-
able only in a limited number of centers worldwide.
As the body has no effective means for removing iron,
the only way to remove excess iron is to use iron binders
(chelators), which allow iron excretion through the urine
and/or stool. As a general rule, patients should start iron
chelation treatment once they have had 10-20 transfu-
sions or when ferritin levels rise above 1000 ng/ml [3].
The first drug available for treatment of iron overload was
deferoxamine (DFO), an exadentate iron chelator that is
not orally absorbed and thus needs parenteral adminis-
tration, usually as a subcutaneous 8- to 12-hour nightly
infusion, 5-7 nights a week. Average dosage is 20-40 mg/
kg body weight for children and 30-50 mg/kg body weight
for adults [3,4]. In high risk cases, continuous administra-
tion of DFO via an implanted delivery system (Port-a-
cath) or subcutaneously, at doses between 50 and 60 mg/
kg per day, were the only options to intensify the chela-
tion treatment before the advent of the combined therapy
with DFO and deferiprone [44]. Implanted delivery sys-
tems are associated with risk of thrombosis and infection.
W ith DFO, iron is excreted both in faeces (about 40%)
and in urine. The most frequent adverse effects of DFO
are local reactions at the site of infusion, such as pain,
swelling, induration, erythema, burning, pruritus, wheals
and rash, occasionally accompanied by fever, chills and
malaise. Other complications, mainly associated with
high doses of DFO in young patients and low ferritin val-
ues are:
• sensorineural hypoacusia, particularly at high fre-
quencies
• ocular toxicity (night-blindness, blurred vision,
decreased visual acuity, impairment of colour vision,
cataract and other disturbances of the eye)
• retarded growth and skeletal changes with a dispro-
portionately short trunk and dysplasia of the long
bones
• infections by Yersinia Enterocolitica, and other
pathogens (Klebsiella Pneumoniae).
It is therefore important to monitor patients receiving
DFO regularly with audiometric and ophthalmologic
tests and with regular evaluation of growth and bone
changes.
The use of DFO decreases morbidity and mortality
among those who are able to comply with regular pro-
longed infusions [47]. However, because of the side
effects and the inconvenient parenteral administration, a
consistent proportion of patients is non-compliant, limit-
ing the usefulness of this chelator [35].
The orphan drug deferiprone (DFP) is an orally active
iron chelator which has emerged from an extensive
search for new treatment of iron overload. Comparative
studies have shown that this chelator, at doses of 75-100
mg/kg/day may be as effective as DFO in removing body
iron [48]. Retrospective and prospective studies have
shown that DFP monotherapy is significantly more effec-
Table 2: Transfusion-dependent complications.
Iron overload
Infections
Known
- Viral (HIV, HCV, HBV, HTLVI, West Nile virus)
- Bacterial
- Parasitic
Rare
- Creutzfeld-Jacob disease
- Emerging and new pathogens
Hemolytic 
reactions
Acute hemolytic reactions
Delayed hemolytic reactions
Autoimmune hemolytic anemia
Non-Hemolytic 
reactions
Allergic and anaphylactic reactions
Febrile non-hemolytic reactions
Transfusion-related acute lung injury (TRALI)
Transfusion-associated graft-versus-host disease
Circulatory overload
Post-transfusion purpuraGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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tive than deferoxamine in decreasing myocardial sidero-
sis in thalassemia major [49-51]. Agranulocytosis is the
most serious side effect associated with the use of DFP,
occurring in about 1% of the patients [48]. More common
but less severe side effects are gastrointestinal symptoms,
arthralgia, zinc deficiency, and fluctuating liver enzymes.
Retrospective studies have shown that DFP treatment is
associated with reduced cardiac morbidity and mortality
[50,52,53]. DFO and DFP can be used in combination to
achieve levels of iron excretion that cannot be achieved
by either drug alone without increasing toxicity [54-59].
Reversal of severe iron-related heart failure with DFO
and DFP combination has been reported in many
patients [44,60-62]. The effect of combined therapy ver-
sus DFO monotherapy on myocardial iron overload was
evaluated in a prospective, randomized, placebo con-
trolled trial, which showed a statistically significant
improvement in myocardial T2* with the combined treat-
ment as compared with DFO and placebo treatment [63].
Combination therapy should be considered as an alterna-
tive to continuous intravenous DFO monotherapy when
an intensive chelation is required.
Deferasirox (DFX) is a once-daily, orally administered
iron chelator that a large program of clinical trials has
shown to be effective in adults and children [64,65]. It
received European Union marketing authorization as an
orphan drug from the EMEA in 2002 and was authorized
for marketing in most countries in 2006. The recom-
mended starting dose of DFX for most patients is 20 mg/
kg/day, although this can be modified to 10 or 30 mg/kg/
day depending on the number of transfusions a patient is
receiving and whether the therapeutic goal is to decrease
or maintain body iron levels. The most frequent adverse
events reported during treatment with DFX include tran-
sient, mild-to-moderate gastrointestinal disturbances and
skin rash. These events rarely require drug discontinua-
tion and most resolve spontaneously. Mild, usually non-
progressive increases in serum creatinine (generally
within the upper limit of normal) has been observed in
approximately a third of patients. Creatinine levels
returned spontaneously to baseline in most of patients
and data from up to 3.5 years of treatment in more than
1000 patients have confirmed that creatinine increase is
non progressive [66]. However, cases of renal failure have
been reported following the postmarketing use of DFX
[67].
(S)-3'-(OH)-desazadesferrithiocin-polyether, magne-
sium salt is an oral once a day iron chelator expected to
excrete iron mainly in the stools, evaluated in experimen-
tal models. Orphan designation of this medicine has been
granted in the United States of America and Europe for
treatment of chronic iron overload in patients with trans-
fusion-dependent anemias. Recently, three main practice
guidelines for the management of iron overload in thalas-
semia major have been published and are available online
[3,68,69].
Treatment of iron overload-related complications
Growth deficiency
Studies evaluating the secretion of growth hormone (GH)
in patients with thalassemia major have yielded contra-
dictory results, limiting the therapeutic use of GH to
those patients proven to have GH deficiency, who may
have a satisfactory response to treatment [70-72]. In cases
with signs of bone toxicity from DFO a reduction of the
dose, or its substitution with an oral chelator, can prevent
progression of bone lesions and improve growth.
Delayed puberty, hypogonadism and assisted reproduction
For delayed puberty in girls, therapy may start with the
administration of ethinyl estradiol (2.5-5 μg daily) for 6
months, followed by hormonal reassessment. If sponta-
neous puberty does not occur within 6 months, ethinyl
estradiol should be used at increasing dosages (from 5-10
μg daily) for 12 months. If breakthrough uterine bleeding
does not occur, a low oestrogenprogesterone hormone
replacement is recommended. For delayed puberty in
males, intramuscular depot-testosterone esters at a dose
of 50-100 mg twice a month should be given, until com-
plete virilisation has been achieved [72]. Topical testos-
terone gel can also be used [73]. When there is a lack of
p u b e r t a l  p r o g r e s s i o n  o v e r  a  y e a r  o r  l o n g e r  ( a r r e s t e d
puberty), testosterone esters in males and oestrogenpro-
gesterone replacement therapy in females is indicated.
In males suffering from azoospermia or astheno-
spermia and asking for fertility treatment, spermatogene-
sis may be induced by combination therapy with hCG
(human chorionic gonadotrophin) and hMG (human
menopausal gonadotrophin) intramuscularly or subcuta-
neously. Moreover, the recent advent of micromanipula-
tion techniques such as intracytoplasmatic sperm
injection (ICSI) has improved conception rates. Females
with thalassemia may have primary or secondary amen-
orrhea, which leads to failure of the reproductive axis
with chronic anovulation. Despite severe hemosiderosis,
ovarian function is preserved in most patients, and they
are still able to increase the estradiol level following stim-
ulation with gonadotrophins, and furthermore produce
ova. Induction of ovulation must be performed under rig-
orous control after a global evaluation of the patient,
including detailed assessment of heart, liver function,
viral infections, endocrinopathies, with particular
emphasis on diabetes control and thrombophilia status
[74]. Pregnant patients with thalassemia need a multidis-
ciplinary approach involving all specialists in the medical
care of thalassemia [75].
Hypothyroidism
Preclinical hypothyroidism is characterized by normal
thyroxine (T4) and free thyroxine (FT4), normal basalGalanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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TSH and TSH slightly increased after the Thyrotropin-
releasing Hormone (TRH) test. A careful follow-up with
an intensification of chelation therapy is required in such
cases. Subclinical hypothyroidism is defined as a normal
serum T4 and FT4 level with a slightly increased TSH
level. It is debatable whether patients with subclinical
hypothyroidism should be treated. If treatment is consid-
ered unnecessary, close monitoring is mandatory. Ther-
apy can be recommended for patients with TSH levels
greater than 10 U/ml, thyroid abnormalities, and vague
symptoms attributable to hypothyroidism. In overt hypo-
thyroidism, characterized by low T4 and FT4 values with
signs and symptoms such as mental and physical slug-
gishness, weight gain, feeling of cold, sleepiness, brady-
cardia and constipation, treatment with increasing doses
of L-thyroxine starting with 25 mg per day is indicated.
Abnormal thyroid function may be reversible at an early
stage through intensive combined chelation [76].
Hypoparathyroidism
Severe hypocalcemia with tetany requires intravenous
administration of calcium under careful electrocardio-
graphic monitoring, followed by oral vitamin D. In milder
forms, calcitriol is the drug of choice, because of its short
half-life and rapid action. A dosage of 0.25-1 μg twice
daily is usually sufficient to normalize calcium and phos-
phate. Because of the risk of hypercalcemia and hypercal-
ciuria, serum calcium level and 24-hour urinary calcium
and phosphate measurements should be carefully moni-
tored, especially at the beginning of treatment and if ele-
vated doses of Vitamin D are administered.
Diabetes and impaired glucose tolerance
Acarbose at the dose of 100 mg (orally with breakfast,
lunch and evening meals) has been used with good
results for impaired glucose tolerance or non-insulin
dependent diabetes mellitus and hyperinsulinism [77].
Patients with diabetes mellitus, may require daily subcu-
taneous injections of insulin. Since treatment of diabetes
in patients with thalassemia major is an additional bur-
den, support from doctors and psychologists is needed.
Investigation of the kidney function and imaging of the
fundi should be carried out to evaluate the presence and
degree of diabetic complications. Intensive iron chelation
therapy with DFO and DFP seems to be associated with
an improvement in glucose intolerance in terms of glu-
cose and insulin secretion, particularly in patients in early
stages of glucose intolerance [78].
Osteoporosis
Since osteoporosis is a progressive disease, prevention is
the basis of the management. No smoking, a calcium-rich
diet, correction of hypogonadism by sex hormone
replacement therapy and regular exercise should be rec-
ommended. Oral calcium supplements should be used
with caution because of the risk of renal stones. Several
bisphosphonates have been used in thalassemia patients
for the treatment of osteoporosis with variable results. To
date, alendronate, pamidronate, and zoledronate seem to
be effective in increasing bone mineral density and nor-
malizing bone turnover, but more controlled trials are
necessary to evaluate their efficacy in reducing fracture
risks in larger thalassemic populations [79].
Splenectomy
If the annual red cell requirement exceeds 180-200 ml/Kg
of RBC (assuming that the Hct of the unit of red cells is
about 75%), splenectomy should be considered, provided
that other reasons for increased consumption, such as
hemolytic reactions, have been excluded. Other indica-
tions for splenectomy are symptoms of splenic enlarge-
ment, leukopenia and/or thrombocytopenia and
increasing iron overload despite good chelation [3].
Bone marrow and cord blood transplantation
Bone marrow transplantation (BMT) remains the only
definitive cure currently available for patients with thalas-
semia. The outcome of BMT is related to the pretrans-
plantation clinical conditions, specifically the presence of
hepatomegaly, extent of liver fibrosis, history of regular
chelation and hence severity of iron accumulation. In
patients without the above risk factors, stem cell trans-
plantation from an HLA identical sibling has a disease-
free survival rate over 90% [80]. The major limitation of
allogenic BMT is the lack of an HLA-identical sibling
donor for the majority of affected patients. In fact,
approximately 25-30% of thalassemic patients could have
a matched sibling donor. BMT from unrelated donors has
been carried out on a limited number of individuals with
beta-thalassemia. Provided that selection of the donor is
based on stringent criteria of HLA compatibility and that
individuals have limited iron overload, results are compa-
rable to those obtained when the donor is a compatible
sib [81]. However, because of the limited number of indi-
viduals enrolled, further studies are needed to confirm
these preliminary findings. If BMT is successful, iron
overload may be reduced by repeated phlebotomy, thus
eliminating the need for iron chelation. Chronic graft-
v e r s u s - h o s t  d i s e a s e  ( G V H D )  o f  v a r i a b l e  s e v e r i t y  m a y
occur in 5-8% of individuals.
Cord blood transplantation from a related donor offers
a good probability of a successful cure and is associated
with a low risk of GVHD [82,83]. For couples who have
already had a child with thalassemia and who undertake
prenatal diagnosis in a subsequent pregnancy, prenatal
identification of HLA compatibility between the affected
child and an unaffected fetus allows collection of placen-
tal blood at delivery and the option of cord blood trans-
plantation to cure the affected child [84]. On the other
hand, in cases with an affected fetus and a previous nor-
mal child, the couple may decide to continue the preg-Galanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
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nancy and pursue BMT later, using the normal child as
the donor.
Management of thalassemia intermedia
Treatment of individuals with thalassemia intermedia is
symptomatic [4,85]. As hypersplenism may cause wors-
ening anemia, retarded growth and mechanical distur-
bance from the large spleen, splenectomy is a relevant
aspect of the management of thalassemia intermedia.
Risks associated with splenectomy include an increased
susceptibility to infections mainly from encapsulated bac-
teria (Streptococcus Pneumoniae, Haemophilus Influen-
zae and Neisseria Meningitidis) and an increase in
thromboembolic events. Prevention of post-splenectomy
sepsis includes immunization against the above men-
tioned bacteria and antibiotic prophylaxis as well as early
antibiotic treatment for fever and malaise. Because of the
elevated prevalence of cholelithiasis and the risks of
cholecystitis in splenectomised patients, the gallbladder
should be inspected during splenectomy and removed in
case with or to prevent gallstones. Treatment of
extramedullary erythropoietic masses, detected by mag-
netic resonance imaging, is based on radiotherapy, trans-
fusions, or hydroxycarbamide. Once leg ulcer has
developed, it is very difficult to manage. Regular blood
transfusions, zinc supplementation and pentoxifylline,
and the use of an oxygen chamber have been proposed
for ulcer treatment. Hydroxycarbamide also has some
benefit, either alone or with erythropoietin. Recently
promising results have been obtained with platelet
derived growth factor. Since patients with thalassemia
intermedia have a high risk of thrombosis, exacerbated by
splenectomy, it is important to be aware of thrombotic
complications. Recommended treatment options include
proper anticoagulation prior to surgical or other high-
risk procedures, platelet anti-aggregating agents in case
of thrombocytosis (platelet count higher than 700,000/
mm3) and low molecular weight heparin in patients with
documented thrombosis. Because individuals with thala-
ssemia intermedia may develop iron overload from
increased gastrointestinal absorption of iron or from
occasional transfusions, chelation therapy is started when
the serum ferritin concentration exceeds 300 ng/ml or
when iron overload is demonstrated by direct or indirect
methods [86]. Supplementary folic acid can be prescribed
to patients with thalassemia intermedia to prevent defi-
ciency from hyperactive bone marrow.
Lifestyle and diet in beta-thalassemia
If the disease is fully compensated by ideal treatment, an
individual with thalassemia major can enjoy a near-nor-
mal lifestyle and experience normal physical and emo-
tional development from childhood to adulthood,
including parenthood.
Patients with thalassemia do not have specific dietary
requirements, unless they have special prescriptions.
Patients already have a heavy treatment schedule and it is
counterproductive to add further restrictions without the
likelihood of clear benefit. During growth, a normal
energy intake with normal fat and sugar content is rec-
ommended. During adolescence and adult life, a diet low
in highly refined carbohydrates may be useful in prevent-
ing or delaying the onset of impaired glucose tolerance or
diabetes. There is no clear evidence that a specific diet is
beneficial in preventing or managing liver disease, unless
at late stages. Increased iron absorption from the intesti-
nal tract is characteristic of thalassemia. The amount
depends on the degree of erythropoiesis, the Hb level and
other potential independent factors. Drinking a glass of
black tea with meals reduces iron absorption from food,
particularly in thalassemia intermedia [85]. However,
there is no evidence that iron-poor diets are useful in
thalassemia major; only foods very rich in iron (such as
liver , many baby foods, breakfast cereals and multivita-
min preparations contain added iron, along with other
vitamin supplements) should be avoided. Since many fac-
tors in thalassemia promote calcium depletion, a diet
containing adequate calcium (e.g. milk, cheese, dairy
products and kale) is always recommended. However,
nephrolithiasis is seen in some adults with thalassemia
major, and calcium supplements should not be given
unless there is a clear indication; instead a low oxalate
diet should be considered.
Patients with thalassemia who remain untransfused or
are on low transfusion regimens have increased folate
consumption and may develop a relative folate deficiency.
Supplements (1 mg/day) may be given if this occurs.
Patients on high transfusion regimens rarely develop this
condition, and usually have no need for supplements.
Ir o n ove r loa d ca uses  vitam in C  t o be  o xi dized a t  a n
increased rate, leading to vitamin C deficiency in some
patients. Fifty mg of vitamin C in children <10 years and
100 mg >10 years at the time of DFO infusion may
increase the 'chelatable iron' available in the body, thus
increasing the efficacy of chelation. However there is cur-
rently no evidence supporting the use of vitamin C sup-
plements in patients on DFP, DFX or combination
treatment. Vitamin C may increase iron absorption from
the gut, labile iron and hence iron toxicity and may there-
fore be particularly harmful to patients who are not
receiving DFO, as iron mobilized by the vitamin C will
remain unbound, causing tissue damage.
The effectiveness and safety of vitamin E supplementa-
tion in thalassemia major has not been formally assessed
and it is not possible to give recommendations about its
use at this time.
Patients with thalassemia should be discouraged from
consuming alcohol, as it can facilitate the oxidative dam-Galanello and Origa Orphanet Journal of Rare Diseases 2010, 5:11
http://www.ojrd.com/content/5/1/11
Page 12 of 15
age of iron and aggravates the effect of HBV and HCV on
liver tissue.
In general, physical activity must always be encouraged
unless there is a precise secondary medical condition.
Conditions requiring special attention include splenom-
egaly, severe heart disease and osteoporosis.
There is no reason for patients with thalassemia to skip
or delay standard recommended vaccinations. To prevent
and minimize the risk of infection, immunization with
the pneucococcal, Haemophilus Influenza and meningo-
coccal vaccines is recommended about two weeks before
splenectomy and after surgery.
It is now universally recognized that thalassemia, like
other chronic diseases, has important psychological
implications. The way in which the family and the patient
come to terms with the disease and its treatment will
have a critical effect on the patient's survival and quality
of life, and a general acceptance by the patient of his/her
own condition constitutes the key to normal develop-
ment from childhood to adulthood. A key role for treat-
ing physicians and other health care professionals is to
h e l p  p a t i e n t s  a n d  f a m i l i e s  t o  f a c e  u p  t o  t h e  d i f f i c u l t
demands of treatment, while maintaining a positive role.
Therapies under investigation
Induction of HbF synthesis can reduce the severity of
beta-thalassemia by improving the imbalance between
alpha and non-alpha globin chains. Several compounds
including 5-azacytidine, decytabine, and butyrate deriva-
tives gave encouraging results in clinical trials [87]. These
agents induce Hb F by different mechanisms not yet well
defined. Their potential in the management of beta-thala-
ssemia syndromes is under investigation.
A butyrate derivative, 2,2-Dimethylbutyric acid,
sodium salt has received orphan designation for betath-
alassemia in the United States of America and in Europe.
The efficacy of hydroxycarbamide treatment in individ-
uals with thalassemia is still unclear. Hydroxycarbamide
has been used as experimental treatment in patients with
thalassemia intermedia to reduce extramedullary masses,
to increase Hb levels, and, in some cases, to improve leg
ulcers. A good response, correlated with particular poly-
morphisms in the beta globin cluster (i.e., C>T at -158 G
gamma), has been reported in individuals with transfu-
sion dependence [88,89]. However, controlled and ran-
domized studies are needed to establish the role of
hydroxycarbamide in the management of thalassemia
major.
The possibility of correction of the molecular defect in
hematopoietic stem cells by transfer of a normal gene via
a suitable vector or by homologous recombination is
being actively investigated [90]. The most promising
results in the mouse model have been obtained with len-
tiviral vectors [90,91]. In 2009, orphan designation was
granted by the European Commission for autologous
haematopoietic stem cells transduced with lentiviral vec-
tor encoding the human beta globin gene for the treat-
ment of beta-thalassemia major and intermedia.
Prognosis
Prognosis of thalassemia minor subjects is excellent. An
increased risk for cholelithiasis, especially in association
with the Gilbert mutation has been demonstrated [92].
Patients with thalassemia intermedia who do not usually
have severe hemosiderosis are less prone to cardiac prob-
lems [11]. However, pulmonary hypertension, throm-
boembolic complications, overwhelming
postsplenectomy sepsis, and the development of hepato-
carcinoma may reduce survival in this group of patients.
The prognosis of betathalassemia major was very grim
before there was any treatment available. With no treat-
ment, the natural history was for death by age five from
infections and cachexia. The first advance in treatment
was the initiation of episodic blood transfusions when the
patient was having a particularly bad time. With the
advent of this type of therapy, survival was prolonged into
the second decade, but it soon became evident that the
treatment that saved lives in children caused death from
cardiac disease in adolescence or early childhood. Prog-
nosis for individuals with betathalassemia major has dra-
m a t i ca l l y  i m p r o v ed  wi t h  t h e  a d v e n t  o f  D F O .  H o w ev e r ,
many transfusion-dependent patients continued to
develop progressive accumulation of iron. This can lead
to tissue damage and eventually death, particularly from
cardiac disease. Advances in red cell transfusion, and the
introduction of new iron chelators and chelation regimes
have further prolonged survival in recent years.
Assessment of myocardial siderosis and monitoring of
cardiac function combined with intensification of iron
chelation have converted a once universally fatal disease
to a chronic illness and an excellent long-term prognosis
is expected for children who have been chelated since a
very young age  [93,94].
Bone marrow transplantation is at present the only
available definitive cure for patients with thalassemia
major.
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